175 related articles for article (PubMed ID: 36634196)
21. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer.
Preston MA; Wilson KM; Markt SC; Ge R; Morash C; Stampfer MJ; Loda M; Giovannucci E; Mucci LA; Olumi AF
JAMA Intern Med; 2014 Aug; 174(8):1301-7. PubMed ID: 24887392
[TBL] [Abstract][Full Text] [Related]
22. Benign Prostatic Hyperplasia.
Langan RC
Prim Care; 2019 Jun; 46(2):223-232. PubMed ID: 31030823
[TBL] [Abstract][Full Text] [Related]
23. 5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer.
Robinson D; Garmo H; Holmberg L; Stattin P
Cancer Causes Control; 2015 Sep; 26(9):1289-97. PubMed ID: 26109464
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis.
Kim JH; Baek MJ; Sun HY; Lee B; Li S; Khandwala Y; Del Giudice F; Chung BI
PLoS One; 2018; 13(10):e0203479. PubMed ID: 30281615
[TBL] [Abstract][Full Text] [Related]
25. [Pharmacological treatment of benign prostatic hyperplasia].
Oelke M; Martinelli E
Urologe A; 2016 Jan; 55(1):81-94; quiz 95-6. PubMed ID: 26676726
[TBL] [Abstract][Full Text] [Related]
26. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
27. The Use of 5-Alpha Reductase Inhibitors and Alpha-1 Blockers Does Not Improve Clinical Outcome in Male Patients Undergoing Radical Cystectomy for Bladder Cancer in Quebec, Canada.
Wissing MD; O'Flaherty A; Dragomir A; Tanguay S; Kassouf W; Aprikian AG
Clin Genitourin Cancer; 2021 Aug; 19(4):371-371.e9. PubMed ID: 33676834
[TBL] [Abstract][Full Text] [Related]
28. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
29. [Benign prostate hyperplasia: success and limitations of pharmacological therapy].
Madersbacher S; Marszalek M
Internist (Berl); 2007 Oct; 48(10):1157-64. PubMed ID: 17426942
[TBL] [Abstract][Full Text] [Related]
30. [Pharmacological treatment of benign prostatic hyperplasia].
Oelke M; Kuczyk MA; Herrmann TR
Urologe A; 2009 Nov; 48(11):1365-75; quiz 1376-7. PubMed ID: 19851747
[TBL] [Abstract][Full Text] [Related]
31. Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the α-adrenergic receptor antagonist.
Qian X; Xu D; Liu H; Lin X; Yu Y; Kang J; Sheng X; Xu J; Zheng S; Xu D; Qi J
Aging Male; 2017 Dec; 20(4):250-256. PubMed ID: 28787260
[TBL] [Abstract][Full Text] [Related]
32. How Would You Manage This Patient With Benign Prostatic Hyperplasia? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Smetana GW; Smith CC; Singla A; Libman H
Ann Intern Med; 2023 Apr; 176(4):545-555. PubMed ID: 37037036
[TBL] [Abstract][Full Text] [Related]
33. Trends in the pharmacological treatment of benign prostatic hyperplasia in the UK from 1998 to 2016: a population-based cohort study.
Ayele HT; Reynier P; Azoulay L; Platt RW; Cabaussel J; Benayoun S; Filion KB
World J Urol; 2021 Jun; 39(6):2019-2028. PubMed ID: 32909173
[TBL] [Abstract][Full Text] [Related]
34. Benign prostatic hyperplasia progression and its impact on treatment.
Djavan B; Waldert M; Ghawidel C; Marberger M
Curr Opin Urol; 2004 Jan; 14(1):45-50. PubMed ID: 15091050
[TBL] [Abstract][Full Text] [Related]
35. Early symptom improvement and discontinuation of 5-α-reductase inhibitor (5ARI) therapy in patients with benign prostatic hyperplasia (BPH).
Kruep EJ; Phillips E; Hogue S; Eaddy M
Ann Pharmacother; 2014 Mar; 48(3):343-8. PubMed ID: 24311727
[TBL] [Abstract][Full Text] [Related]
36. Risk stratification for benign prostatic hyperplasia (BPH) treatment.
Emberton M; Fitzpatrick JM; Rees J
BJU Int; 2011 Mar; 107(6):876-80. PubMed ID: 21265993
[TBL] [Abstract][Full Text] [Related]
37. Association of benign prostatic hyperplasia and subsequent risk of bladder cancer: an Asian population cohort study.
Fang CW; Liao CH; Wu SC; Muo CH
World J Urol; 2018 Jun; 36(6):931-938. PubMed ID: 29427001
[TBL] [Abstract][Full Text] [Related]
38. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
39. Risk Analysis of Prostate Cancer Development Following Five-alpha Reductase Inhibitor Treatment for Benign Prostate Hyperplasia.
Chang LW; Wang SS; Yang CK; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Li JR
Anticancer Res; 2023 Jan; 43(1):485-491. PubMed ID: 36585197
[TBL] [Abstract][Full Text] [Related]
40. Current status of 5alpha-reductase inhibitors in the treatment of benign hyperplasia of prostate.
Kumar VL; Wahane VD
Indian J Med Sci; 2008 Apr; 62(4):167-75. PubMed ID: 18445985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]